ST未名：前三季度实现营收2.12亿元，第三季度单季营收较上半年翻番

Core Viewpoint - ST Unimed (002581.SZ) reported a significant increase in revenue for Q3, achieving 141 million yuan, which is double the total revenue of the first two quarters of the year, leading to a total revenue of 212 million yuan for the first three quarters [1] Group 1: Financial Performance - The company faced challenges in the first half of the year due to the suspension of production and sales at its subsidiary Tianjin Unimed, resulting in poor revenue and profit performance [1] - The financial performance improved in Q3, aided by the accelerated investment and consolidation of Sichuan Gukang Pharmaceutical Co., which is expected to contribute significantly to the company's overall financial results [1] - Gukang Pharmaceutical is projected to achieve revenues of 73.93 million yuan and a net profit of 4.15 million yuan in 2024, with net profit accelerating to 9.85 million yuan in the first four months of 2025, surpassing the total for 2024 [1] Group 2: Business Development - The company is focusing on sustainable development and has a robust pipeline of core products, including the nerve growth factor injection product [2] - The fully-owned subsidiary Shandong Yandu Biotechnology is developing a range of biopharmaceuticals, including a second-generation nerve growth factor eye drop, which is entering Phase III clinical trials [2] - The Chinese ophthalmic drug market is expected to grow at a compound annual growth rate of 19.1% from 2024 to 2030, indicating a significant market opportunity for the company's products [2] Group 3: Strategic Initiatives - The company is actively promoting rectification measures for Tianjin Unimed and is progressing with the construction of the Shandong Unimed Biopharmaceutical Industrial Park, which is set to commence in 2024 [3] - These initiatives are expected to enhance the company's operational performance and governance, potentially leading to continued revenue and profit recovery in the future [3]